Home › Funds › OBERWEIS ASSET MANAGEMENT INC/ › ARQT

OBERWEIS ASSET MANAGEMENT INC/ position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

OBERWEIS ASSET MANAGEMENT INC/ reported holding 1,372,941 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$36.0M, representing 0.74% of its reported portfolio and ranking #39 among its reported holdings. OBERWEIS ASSET MANAGEMENT INC/ has disclosed ARQT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)1.37M sh
Reported value held$36.00M
Portfolio Weight0.74%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How OBERWEIS ASSET MANAGEMENT INC/'s ARQT position evolved

OBERWEIS ASSET MANAGEMENT INC/ first disclosed a stake in ARQT in Q4 2025 at 808,400 shares (US$23.5M). The position peaked in Q2 2026 at 1,372,941 shares, worth US$36.0M. Across 3 filings, OBERWEIS ASSET MANAGEMENT INC/ increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,372,941 shares valued at US$36.0M — an increase of 7,000 shares quarter over quarter.. Notable position changes include a 69% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 808.40K $23.48M New
Q1 2026 1.37M $32.18M Add
Q2 2026 1.37M $36.00M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has OBERWEIS ASSET MANAGEMENT INC/ held ARQT?

OBERWEIS ASSET MANAGEMENT INC/ has disclosed ARQT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is OBERWEIS ASSET MANAGEMENT INC/'s current position in ARQT?

As of Q2 2026, OBERWEIS ASSET MANAGEMENT INC/ holds 1.37M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $36.00M, representing 0.74% of its reported portfolio and ranking #39.

Has OBERWEIS ASSET MANAGEMENT INC/ been buying or selling ARQT?

In the latest 13F filing (Q2 2026), OBERWEIS ASSET MANAGEMENT INC/ increased its position in ARQT. The position peaked in Q2 2026 at 1.37M shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.